What ACE-083 is

ACE-083 is a recombinant fusion protein developed by Acceleron Pharma: a modified domain of human follistatin linked to the Fc fragment of human immunoglobulin G2. This is worth stating up front: ACE-083 is not a peptide, unlike most compounds in this reference, and it is not a monoclonal antibody. It is a protein ligand trap, a soluble decoy that binds extracellular proteins before they can reach their receptor.

A ligand trap, not a receptor blocker

Skeletal muscle is held under continuous inhibitory control by ligands of the TGF-β superfamily. Surface plasmon resonance and cell-based assays showed that ACE-083 binds and potently neutralises myostatin (GDF8), activin A, activin B and GDF11 [1]. By removing that brake, the protein allows muscle to grow.

Here lies a distinction that is often blurred. Bimagrumab is a monoclonal antibody that blocks the ActRII receptor itself and is given systemically, intravenously. ACE-083 instead intercepts the ligands in the extracellular space and is injected directly into a muscle. A further relative is ACE-031 (soluble ActRIIB-Fc), also an Acceleron programme, but systemic. ACE-083 is the only member of this group engineered to be local.

How the locality was engineered

Locality here is not a side effect but a design decision. The follistatin domain has high affinity for heparin and extracellular matrix components [1]. After intramuscular injection the protein effectively adheres to the matrix of the muscle it was injected into and stays there, while the fraction that reaches the circulation is rapidly inactivated.

Preclinical results matched the design: dose-dependent hypertrophy of the injected muscle only in wild-type mice and in models of Charcot-Marie-Tooth disease (CMT) and Duchenne muscular dystrophy, with no evidence of systemic muscle effects and no endocrine perturbation [1]. The intent was targeted: focal and asymmetric myopathies, where weakness is concentrated in specific muscles and a systemic intervention looks excessive.

Preclinical data: volume and force together

In the same work ACE-083 increased more than mass. Isometric contractile force of the injected tibialis anterior rose in situ in wild-type mice and in disease models, and ankle dorsiflexion torque increased in CMT mice [1]. In animals, in other words, the gain in volume was accompanied by a gain in force. It is precisely this link that failed to reproduce in humans, the central thread of the whole ACE-083 story.

The first human study

Phase 1 (NCT02257489) was a randomised, double-blind, placebo-controlled dose-ranging study in 58 postmenopausal women: 42 received ACE-083 at 50–200 mg and 16 placebo, administered unilaterally into the rectus femoris (RF) or tibialis anterior (TA) as one or two doses three weeks apart [2].

Maximum increases in muscle volume were 14.5% ± 4.5% for RF and 8.9% ± 4.7% for TA. There were no serious adverse events, no dose-limiting toxicities and no discontinuations due to adverse events. But the signal that would decide the molecule's fate was already audible: no significant changes in mean muscle strength were observed [2].

Phase 2: facioscapulohumeral muscular dystrophy (FSHD)

The FSHD study (NCT02927080) had two parts: an open-label ascending-dose part (37 participants) and a randomised double-blind part (58 participants) in which ACE-083 240 mg/muscle or placebo was injected bilaterally every three weeks into the biceps brachii (BB) or TA for six months, followed by six months open label [3].

The primary MRI (magnetic resonance imaging) endpoint was met: the treatment difference in total muscle volume (TMV) versus placebo was 16.4% (90% CI 9.8–23.0; p < 0.0001) in the BB group and 9.5% (3.2–15.9; p = 0.01) in the TA group. Contractile muscle volume (CMV) increased in both groups and fat fraction (FF) decreased in the TA group. Yet there were no consistent improvements in functional or patient-reported outcome measures in either group, even with up to 12 months of treatment. The most common adverse events were mild or moderate injection-site reactions [3].

Phase 2: Charcot-Marie-Tooth disease (CMT)

The CMT study (NCT03124459) enrolled 63 adults with CMT1 or CMTX. In the randomised part, ACE-083 240 mg/muscle was injected bilaterally into the TA every three weeks for approximately six months [4].

The pattern repeated almost verbatim: total muscle volume increased significantly versus placebo (least-squares mean difference 13.5%; p = 0.0096), but fat fraction and all other functional outcomes were not significantly improved. Tolerability was good, dominated by mild to moderate injection-site reactions [4].

In March 2020 Acceleron discontinued development of ACE-083. The FSHD study, the CMT study and the long-term extension study (NCT03943290) are all listed as terminated. ACE-083 is not approved as a medicine in any jurisdiction.

The central finding: volume is not function

ACE-083's scientific value turned out to be different from the one intended. Pharmacologically the molecule did exactly what it promised: it grew muscle precisely where it was injected, reproducibly, safely and confirmed by MRI across three independent cohorts of healthy volunteers, FSHD patients and CMT patients.

And yet the added muscle mass did not translate into added strength or function. One nuance matters: in the FSHD study it was contractile volume that increased, and fat fraction in the TA group actually fell [3], so the added tissue was not merely fat or oedema. Function still did not move.

ACE-083 remains one of the cleanest experimental demonstrations that muscle volume and useful muscle function can be dissociated. In neuromuscular disease where weakness is driven by denervation (CMT) or by a primary dystrophic process (FSHD), making the muscle bigger does not, on this evidence, fix the problem. That has direct consequences for future trial design: hypertrophy as a surrogate endpoint proved a poor predictor of clinical benefit.

Limits of the evidence

  • All human data come from direct intramuscular injection into specific muscles (RF, TA, BB). There are no systemic-administration data, the molecule was deliberately engineered not to act systemically.
  • Development stopped at phase 2. No phase 3 trials, no regulatory dossier and no long-term follow-up exist.
  • Only two indications were studied (FSHD and CMT) plus healthy volunteers. Hypotheses about sarcopenia, localised post-injury atrophy or disuse atrophy have not been tested in humans.
  • Phase 1 was conducted exclusively in postmenopausal women [2], which limits generalisation to other populations.
  • Long-term safety of repeated injection beyond the 12 months described is unknown.

Where it sits in the catalogue

ACE-083 belongs to the Muscle Growth category but works on a fundamentally different principle from the other compounds there. Where IGF-1 LR3 amplifies an anabolic signal through the IGF-1R receptor, ACE-083 amplifies nothing, it releases a brake by intercepting inhibitors of muscle growth. These are two opposite routes to one goal, and they are not interchangeable.

Reagent status

ACE-083 is supplied strictly for laboratory research use (RUO). It is not a medicine, supplement or food; it is not intended for human or veterinary consumption, has no approval from any regulator, and has no established human dose. The doses cited above are parameters of published clinical trials, not recommendations.